CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) investigated in research involving growth hormone signaling, IGF-1 pathways, endocrine communication, and peptide pharmacokinetics. The compound is available in two commonly discussed forms: CJC-1295 No-DAC and CJC-1295 with DAC, which differ in their structural characteristics and duration of activity.

NXTSTATE supplies CJC-1295 as a research-grade lyophilized peptide with ≥99% HPLC purity. Each lot undergoes analytical verification, including HPLC and mass spectrometry, and is accompanied by a third-party Certificate of Analysis.

CJC-1295 and GHRH Signaling

CJC-1295 is based on the structure of GHRH and is designed for experimental investigation of the GHRH receptor pathway. Research models commonly examine how activation of this pathway influences growth hormone release and downstream IGF-1 signaling.

The compound’s modified structure has attracted interest because it can provide greater resistance to enzymatic degradation than native GHRH. This characteristic has made CJC-1295 a frequently studied material in investigations of peptide stability, receptor signaling, and endocrine responses.

No-DAC and DAC Forms

The two commonly referenced forms of CJC-1295 are differentiated by the presence or absence of the Drug Affinity Complex (DAC).

CJC-1295 No-DAC is generally investigated in models where researchers want to examine a shorter-acting GHRH analogue and GH signaling patterns closer to transient stimulation.

CJC-1295 with DAC incorporates the Drug Affinity Complex, which alters its pharmacokinetic behavior and extends its interaction with circulating proteins. This form is therefore relevant to research examining prolonged GHRH-receptor pathway activity and sustained endocrine signaling.

Because these forms have different structural and pharmacokinetic characteristics, researchers should identify the specific CJC-1295 form required by their experimental protocol before sourcing material.

Research Applications

CJC-1295 has been investigated across a broad range of experimental contexts. Research has examined its relationship with growth hormone secretion, IGF-1 signaling, body composition, metabolic parameters, bone-related biology, sleep architecture, and endocrine regulation.

Laboratory studies may focus on:

• GHRH receptor activation
• Growth hormone secretion and pulsatility
• GH/IGF-1 signaling
• Peptide stability and pharmacokinetics
• Endocrine receptor interactions
• Metabolic and body-composition models
• Sleep and neuroendocrine research

CJC-1295 has also been studied alongside growth hormone secretagogues such as Ipamorelin and GHRP-6. These combinations provide researchers with experimental models for examining interactions between GHRH-mediated and GHS-receptor pathways.

CJC-1295 Peptide Specifications

Analytical Quality and Lot Verification

For researchers sourcing a CJC-1295 peptide vial, analytical documentation provides important information about the identity and reported purity of the material. NXTSTATE evaluates each batch using HPLC analysis and mass spectrometry, with additional quality-control screening performed according to its laboratory procedures.

Each Certificate of Analysis is associated with the relevant production lot, allowing researchers to connect the analytical documentation with the material supplied.

The lyophilized format also supports controlled laboratory storage and handling according to the supplier’s product documentation and established research protocols.

CJC-1295 as a Research Compound

The phrase CJC-1295 growth peptide is frequently used in commercial searches, but the more precise scientific description is a synthetic GHRH analogue. Its research relevance comes from its interaction with the GHRH signaling pathway and the ability to investigate downstream GH and IGF-1-related processes.

Storage and Handling

NXTSTATE supplies CJC-1295 in lyophilized form. The material should be stored and handled according to the supplier’s current documentation and applicable laboratory SOPs.

Researchers should follow validated procedures for preparation and experimental handling, minimize unnecessary environmental exposure, and avoid repeated freeze-thaw cycles where applicable.

Frequently Asked Questions

What is CJC-1295 peptide?
CJC-1295 is a synthetic GHRH analogue studied for its interaction with GHRH receptors and its effects on growth hormone and IGF-1-related signaling in research models.

What is the difference between CJC-1295 No-DAC and CJC-1295 with DAC?
The primary distinction is the presence of the Drug Affinity Complex. No-DAC and DAC forms have different pharmacokinetic characteristics and are therefore used in different experimental research models.

What is the purity of NXTSTATE CJC-1295?
NXTSTATE specifies ≥99% purity based on HPLC testing, with mass spectrometry used as part of identity verification.

What does a CJC-1295 peptide vial contain?
NXTSTATE supplies CJC-1295 as a white to off-white lyophilized powder. Specific vial quantities should be confirmed against the current product listing and lot documentation.

Is CJC-1295 a medical product?
The NXTSTATE research material is not intended as a medical product. It is supplied solely for laboratory research and is not intended for human or veterinary use, diagnosis, treatment, or disease prevention.

Research Use Disclaimer

Research use only. Not for human or veterinary use. CJC-1295 is supplied as a laboratory research material and is not intended for medical, cosmetic, food, or veterinary applications. Purchasers and researchers are responsible for following applicable laws, institutional requirements, laboratory SOPs, and supplier documentation.